Magnetic resonance spectroscopy (MRS) is proposed in addition to magnetic resonance
imaging (MRI) to help in the characterization of brain tumours by detecting metabolic
alterations that may be indicative of the tumour class. MRS can be routinely performed
on clinical magnets, within a reasonable acquisition time and if performed under adequate
conditions, MRS is reproducible and thus can be used for longitudinal follow-up of
treatment. MRS can also be performed in clinical practice to guide the neurosurgeon
into the most aggressive part of the lesions or to avoid unnecessary surgery, which
may furthermore decrease the risk of surgical morbidity.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2009 Published by Elsevier Inc.
